期刊文献+

羟基乙酸乙基纤维素微球的研制 被引量:2

Preparation of glycolic acid ethyl cellulose microspheres
下载PDF
导出
摘要 目的研究用于肝动脉栓塞治疗的羟基乙酸乙基纤维素微球的制备方法及其体外释药特征。方法选用乙基纤维素为载体,加入羟基乙酸,采用复乳法制备羟基乙酸乙基纤维素微球,以外观、粒径、载药量、包封率为考察指标,从微球的圆整度、光滑度、大小均匀度、含药量对微球综合评价,并采用恒温振荡透析法测定微球的体外药物释放特性。结果和结论羟基乙酸乙基纤维素微球外观光滑,球形圆整,平均粒径(233.38±1.62)μm,载药量114.32μg/mg,包封率78.61%,微球体外可释放药物72 h。羟基乙酸乙基纤维素微球可满足进一步动物实验要求,为化学腐蚀性药物用于肝动脉栓塞的研究提供重要的参考依据。 Objective To prepare glycolic acid ethyl cellulose microspheres(GAECM) for hepatic artery embolization treatment and to investigate their in vitro release property.Methods GAECM was prepared using ethyl cellulose as a carrier,adding glycolic acid,by a double emulsion method.The appearance,particle size,drug loading,and encapsulation efficiency were used as indices to assess the roundness,smoothness,size uniformity,and drug contents of the microspheres.The in vitro release characteristics of the microspheres were determined by constant temperature oscillation dialysis.Results and conclusion The prepared GAECM has a smooth round appearance,with a mean diameter of(233.38±1.62) μm,a mean drug loading of 114.32 μg/mg,an encapsulation efficiency of 78.61%,and a release period of 72 h.The microspheres can meet the requirements of further animal experiments,which provides important reference for using chemical corrosion in drugs used for hepatic arterial embolization studies.
出处 《第二军医大学学报》 CAS CSCD 北大核心 2012年第5期532-535,共4页 Academic Journal of Second Military Medical University
基金 国家自然科学基金(30973458)~~
关键词 羟基乙酸 乙基纤维素 微球 体外释药 glycolic acid ethyl cellulose microspheres in vitro release
  • 相关文献

参考文献6

二级参考文献62

共引文献58

同被引文献41

  • 1刘太锋,祖茂衡.海藻酸钠微球血管栓塞剂(KMG)肝动脉化疗栓塞治疗原发性肝癌[J].徐州医学院学报,2005,25(2):126-129. 被引量:14
  • 2屈元姣,刘陶文.肝癌的非手术局部治疗[J].内科,2007,2(2):271-273. 被引量:3
  • 3Altekruse S F, McGlynn K A,Reichman M E. Hepatocellular carcinoma incidence,mortality,and survival trends in the Unit- ed States from 1975 to 2005[J]. J Clin Oncol,2009,27:1485- 1491.
  • 4Parkin D M, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002[J].CA Cancer J Clin, 2005,55 : 74-108.
  • 5Brown D B,Geschwind J F, Soulen M C, Millward S F, Sacks D. Society of Interventional Radiology position statement on chemoembolization of hepatic malignancies[J]. J Vasc Interv Radiol, 2006,17 : 217-223.
  • 6Vogl T J,Naguib N N,NouEldin N E,Rao P,Emami A H, Zangos S, et al. Review on transarterial chemoembolization in hepatocellular carcinoma: palliative, combined, neoadjuvant, bridging,and symptomatic indications[J]. Eur J Radiol, 2009, 72:505-516.
  • 7Lencioni R. Loco regional treatment of hepatocellular carcino- ma[J]. Hepatology, 2010,52 : 762-773.
  • 8Takayasu K, Arii S, Ikai I, Omata M, Okita K, Ichida T, et al. Prospective cohort study of transarterial chemoembolization for unreseetable hepatocellular carcinoma in 8 510 patients [J]. Gastroenterology, 2006,131 : 461-469.
  • 9Shin S W. The current practice of transarterial chemoemboliza- tion for the treatment of hepatocellular carcinoma[J]. Korean J Radiol, 2009,10 : 425-434.
  • 10Guan Y S, Liu Y. Interventional treatments for hepatocellular carcinoma[J]. Hepatobiliary Pancreat Dis Int, 2006, 5: 495- 500.

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部